Videos

4 experts are featured in this series.

Panelists discuss how analysis from the Miami Breast Cancer Conference showing 60% of eligible early breast cancer patients are not receiving CDK4/6 inhibitors reflects disparities between academic and community settings, particularly affecting older patients and those with fewer lymph nodes, while identifying remaining unmet needs including better management of quality-of-life impacting adverse effects like fatigue and diarrhea, reducing the burden of frequent laboratory monitoring, and addressing financial toxicity and administrative barriers that affect both patients and health care staff.

4 experts are featured in this series.

Panelists discuss how they are excited about future CDK4/6 inhibitor data including oral SERDs to replace fulvestrant injections, triplet combinations with newer agents, expansion into HER2-positive settings, and the potential role of ctDNA monitoring, while emphasizing key patient education points such as explaining mechanism of action differences from chemotherapy, managing expectations about common adverse effects, setting parameters for when to contact the care team, and providing resources like ChemoCare while also educating health care teams through primary literature and electronic health record care plans.

3 experts in this video

Panelists discuss how subcutaneous immune checkpoint inhibitors transform cancer care delivery by streamlining clinical workflows through faster administration in alternative care settings, improving patient quality of life by reducing treatment time and allowing greater flexibility in scheduling, and expanding access through home-based programs that serve rural and underserved populations while maintaining comprehensive monitoring and support systems.

4 experts are featured in this series.

Panelists discuss how pharmacists play a crucial role in toxicity management and monitoring for CDK4/6 inhibitors (including proper QTc calculations, lab monitoring thresholds, and diarrhea mitigation strategies), how they incorporate NCCN guideline recommendations into clinical practice while identifying patients who might fall through the cracks (especially those not receiving chemotherapy), and how they consider sequencing CDK4/6 inhibitors based on postMONARCH trial data for patients with soft progression or low tumor burden without actionable mutations.

4 experts are featured in this series.

Panelists discuss how treatment selection between CDK4/6 inhibitors in early-stage breast cancer is primarily driven by trial eligibility criteria with abemaciclib being preferred when qualified, while in metastatic settings ribociclib is often favored due to overall survival data, and how adverse event profiles differ significantly among the 3 agents (neutropenia with palbociclib/ribociclib, QTc prolongation and drug interactions with ribociclib, and early-onset diarrhea with abemaciclib that typically improves with supportive care management).

3 experts in this video

Panelists discuss how IV administration of immune checkpoint inhibitors creates operational challenges, including infusion chair bottlenecks, complex scheduling, venous access difficulties, and time burdens for patients, while subcutaneous formulations offer potential solutions through simplified delivery, reduced infusion center strain, and improved patient convenience.

A panelist discusses how pharmacists can optimize shingles vaccine uptake by addressing cost barriers through insurance coverage, ensuring consistent vaccine recommendations across all health care touchpoints, and using a presumptive approach that assumes patients want protection rather than asking if they want a vaccine.